Sign inJoin waitlistJoin the waitlist

Anthony Hunter

Medical Director, Immediate Care Center · Winship Cancer Institute at Emory Midtown

Credentials: · · · · · ·

History

Immediate Care Center · Winship Cancer Institute at Emory Midtown
Present
Winship Cancer Institute at Emory Midtown
Present
Emory University School of Medicine
Present

Hematology and Medical Oncology
University of South Florida Morsani College of Medicine
2017–2020
Internal Medicine
Emory University School of Medicine
2014–2017
Medical College of Wisconsin
2010–2014

Research

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients
Leukemia · 2020 · 92 citations
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Blood Advances · 2021 · First of 13 authors · 70 citations
Current status and new treatment approaches in TP53 mutated AML
Review · Best Practice & Research Clinical Haematology · 2019 · First of 2 authors · 70 citations

Eric Padron
15 papers
DS
David Sallman
10 papers
RK
Rami Komrokji
9 papers
Ghaith Abu-Zeinah
6 papers
Mrinal Patnaik
6 papers
Prithviraj Bose
5 papers
Ruben Mesa
5 papers
Abdulraheem Yacoub
4 papers
JL
Jeffrey Lancet
4 papers
Lucia Masarova
4 papers
OC
Onyee Chan
4 papers
Abhishek Mangaonkar
3 papers

Clinical trials

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Site PI · Recruiting · Phase 3
Takeda
2026–2034
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2030
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Site PI · Recruiting · Phase 2
Theradex
2026–2028
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Site PI · Recruiting · Phase 2
Icahn School of Medicine at Mount Sinai
2023–2028